5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 28.39▲ | 28.22▲ | 28.21▲ | 26.82▲ | 26.42▲ |
MA10 | 28.17▲ | 28.11▲ | 27.92▲ | 28.26▲ | 19.57▲ |
MA20 | 28.17▲ | 27.72▲ | 27.05▲ | 26.35▲ | 14.55▲ |
MA50 | 27.86▲ | 26.68▲ | 27.78▲ | 18.16▲ | 11.44▲ |
MA100 | 27.08▲ | 27.80▲ | 27.90▲ | 13.75▲ | 42.14▼ |
MA200 | 26.51▲ | 27.65▲ | 23.16▲ | 11.32▲ | 104.90▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.046▲ | 0.063▲ | 0.243▲ | -0.532▼ | 2.227▲ |
RSI | 63.284▲ | 64.482▲ | 60.628▲ | 66.347▲ | 72.239▲ |
STOCH | 78.996 | 61.983 | 78.941 | 38.120 | 89.128▲ |
WILL %R | -12.791▲ | -8.616▲ | -4.635▲ | -42.222 | -14.250▲ |
CCI | 183.537▲ | 194.981▲ | 134.164▲ | 19.429 | 113.409▲ |
Monday, October 13, 2025 03:01 AM
Barclays initiated coverage on eight names, including Abivax, AnaptysBio, Celldex, Corvus Pharmaceuticals, Monopar Therapeutics, Oruka Therapeutics, RAPT Therapeutics, and Tvardi Therapeutics.
|
Monday, September 29, 2025 06:40 AM
Rapt Therapeutics (RAPT) announced that the U.S. FDA has cleared Rapt’s Investigational New Drug Application to proceed to a Phase 2b clinical trial of RPT904 for the treatment of patients with food ...
|
Sunday, September 28, 2025 10:00 PM
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
16/10/25 | 27.26 | 29.00 | 27.07 | 28.93 | 162,100 |
15/10/25 | 25.41 | 27.955 | 25.29 | 27.03 | 166,116 |
14/10/25 | 25.74 | 26.23 | 24.80 | 25.00 | 163,800 |
13/10/25 | 27.41 | 27.41 | 24.25 | 26.35 | 264,200 |
10/10/25 | 29.94 | 29.955 | 26.49 | 26.79 | 191,900 |
09/10/25 | 29.47 | 30.36 | 28.65 | 30.015 | 139,000 |
08/10/25 | 29.27 | 30.93 | 28.307 | 29.44 | 393,000 |
07/10/25 | 29.73 | 30.70 | 26.93 | 29.02 | 343,100 |
06/10/25 | 30.35 | 32.35 | 29.53 | 29.87 | 386,900 |
03/10/25 | 29.26 | 31.76 | 28.07 | 30.14 | 532,600 |
|
|
||||
|
|
||||
|
|